Clinical Trial Update: Basiliximab in Moderate to Severe Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Basiliximab for moderate to severe ulcerative colitis has completed (sponsor Cerimon Pharmaceuticals).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Simulect (Basiliximab)

Snippet

Sponsor: Cerimon Pharmaceuticals | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED